Prof. Hania Szajewska will lead the Company's
clinical studies in Europe. Dr.
Carina Venter will lead key studies
in the U.S.
VANCOUVER, BC, April 12, 2021 /CNW/ - ELSE NUTRITION
HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE:
0YL) ("Else" or the "Company") the
Plant-Based baby, toddler and children nutrition company, is
pleased to announce the addition of 2 world-class experts to
its Scientific Advisory Board.
"The importance of these 2 new Advisory Board members cannot be
understated. Prof. Szajewska and Dr. Venter bring immense and
invaluable expertise which significantly bolsters our pathway
toward commercializing clean label, plant-based infant nutrition in
both the U.S. and European markets," said Hamutal Yitzhak, Else CEO & Co-Founder.
Professor Hania Szajewska, MD, is
Professor and Chair of the Department of Pediatrics at the Medical
University of Warsaw. Until
June 2019, she served as the
Editor-in-Chief of the Journal of Pediatric Gastroenterology and
Nutrition. Previously, Prof. Szajewska served as a member of
the Council and then as the General Secretary of the European
Society for Pediatric Gastroenterology, Hepatology and Nutrition
(ESPGHAN). She also served as the Secretary of the ESPGHAN
Committee on Nutrition. Most recently (January 2019), she joined the Board of Directors
of the International Scientific Association for Probiotics and
Prebiotics. She has co-authored more than 320 publications. In
2020, Prof. Szajewska has been ranked as one of the world's top 2%
most-cited researchers. She will lead Else's clinical studies in
Europe.
Dr. Carina Venter obtained her
PhD from the University of Southampton. She moved from the UK in
2015 where she had been performing research into food allergies and
allergy prevention as a Senior Lecturer at the University of
Portsmouth at the David Hide
Centre on the Isle of Wight. Dr. Venter (PhD RD) is currently
an Associate Professor of Pediatrics, Section of Allergy/Immunology
at the Children's Hospital Colorado and University of Colorado Denver, where she is
conducting research in allergy prevention and working with children
with food allergies. She is a member of American, European,
and British Allergy Societies. She is a member of European
and American food allergy guidelines on Allergy Prevention. She was
also a member of the NICE (UK) and National Institutes for Allergy
and Infectious Diseases Food Allergy guidelines. She will lead
Else's hypoallergenicity studies in the U.S.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company
focused on developing innovative, clean and plant-based food and
nutrition products for infants, toddlers, children, and adults. Its
revolutionary, plant-based, non-soy, formula is a clean-ingredient
alternative to dairy-based formula. Else Nutrition (formerly INDI)
won the "2017 Best Health and Diet Solutions" award at the Global
Food Innovation Summit in Milan.
Else Plant-Based Complete Nutrition for Toddlers was recently
ranked as the #1 Top seller in the baby and toddler formula
category on Amazon. The holding company, Else Nutrition Holdings
Inc., is a publicly traded company, listed as TSX Venture Exchange
under the trading symbol BABY and is quoted on the US OTC Markets
QX board under the trading symbol BABYF and on the Frankfurt
Exchange under the symbol 0YL. Else's Executives includes
leaders hailing from leading infant nutrition companies. Many
of Else advisory board members had past executive roles in
companies such as Mead Johnson, Abbott Nutrition, Plum Organics and
leading infant nutrition Societies, and some of them
currently serve in different roles in leading medical centers and
academic institutes such as Boston Children's Hospital, Pediatrics
at Harvard Medical School, USA, Tel Aviv
University, Schneider Children's Medical Center of
Israel, Rambam Medical Center and
Technion, Israel and University
Hospital Brussels, Belgium.
For more information, visit: elsenutrition.com or
@elsenutrition on Facebook and Instagram.
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services
provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute
"forward-looking statements" within the meaning of applicable
securities legislation. Forward-looking statements are typically
identified by words such as "will" or similar expressions.
Forward-looking statements in this press release include statements
with respect to the anticipated dates for filing the Company's
financial disclosure documents. Such forward-looking
statements reflect current estimates, beliefs and assumptions,
which are based on management's perception of current conditions
and expected future developments, as well as other factors
management believes are appropriate in the circumstances. No
assurance can be given that the foregoing will prove to be correct.
Forward-looking statements made in this press release assume, among
others, the expectation that there will be no interruptions or
supply chain failures as a result of COVID 19 and that the
manufacturing, broker and supply logistic agreement with the
Company do not terminate. Actual results may differ from the
estimates, beliefs and assumptions expressed or implied in the
forward-looking statements. Readers are cautioned not to
place undue reliance on any forward-looking statements, which
reflect management's expectations only as of the date of this press
release. The Company disclaims any obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/globally-acclaimed-pediatrics-nutrition-and-allergies-experts-join-elses-advisory-board-301266195.html
SOURCE Else Nutrition Holdings Inc.